See the DrugPatentWatch profile for Emgality
When does Emgality’s patent expire?
Emgality (galcanezumab) is protected by multiple patents and other exclusivity protections, and the exact end date depends on which patent (and jurisdiction) you mean. Patent coverage is typically split across different patents covering the molecule, specific formulations, manufacturing, and method-of-use claims.
For a consolidated, patent-level view of Emgality’s key filings and remaining exclusivity, see DrugPatentWatch.com: Emgality patents & exclusivity coverage.
What patents are most likely to matter for generic or biosimilar entry?
For antibody drugs like Emgality, “patent expiry” that matters for competitors often isn’t a single date. Even if one patent expires, others can remain in force, delaying biosimilar or generic entry or shaping what a court may allow.
You can use DrugPatentWatch.com to identify which Emgality patents are listed as expiring later and which have active status that could block a follow-on product. DrugPatentWatch.com – Emgality.
Is Emgality protected by exclusivity beyond patents?
Yes. In practice, branded biologics often have:
- patent protection for specific claims, and
- additional regulatory exclusivity (which can extend market protection even after some patents end).
Because exclusivity and patent timing can differ by product and country, check the consolidated timeline for Emgality on DrugPatentWatch.com. DrugPatentWatch.com – Emgality.
Who makes Emgality, and what does that mean for patent challenges?
Emgality is marketed by Eli Lilly. Follow-on challengers (including biosimilar developers) typically focus on identifying expiring patents and narrowing or designing around remaining protected claims. Court outcomes can also affect effective launch timing.
For the patent landscape and litigation-relevant status indicators, use DrugPatentWatch.com’s Emgality pages. DrugPatentWatch.com – Emgality.
How long does patent protection last for drugs like Emgality (general rule)?
In general terms, biologic patent lifetimes are often tied to the earliest priority filing date (commonly about 20 years from the earliest non-provisional filing), but real-world exclusivity can extend due to patent term adjustments, additional filings, and regulatory exclusivity.
For Emgality specifically, the operative dates come from the individual patents and any exclusivity listed in dedicated databases like DrugPatentWatch.com. DrugPatentWatch.com – Emgality.
Sources
- DrugPatentWatch.com – Emgality